Sino Biopharmaceutical Limited Fundamental Analysis (HKSE: 1177.HK)
Sino Biopharmaceutical Limited Fundamental Analysis (HKSE: 1177.HK)
Sino Biopharmaceutical Limited (HKSE: 1177.HK) shows weak financial fundamentals with a PE ratio of 36.85, profit margin of 7.36%, and ROE of 7.32%. The company generates $31.5B in annual revenue with strong year-over-year growth of 10.28%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 45.4/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 1177.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1177.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate1177.HK shows balanced valuation metrics.
Growth Score
Moderate1177.HK shows steady but slowing expansion.
Financial Health Score
Excellent1177.HK maintains a strong and stable balance sheet.
Profitability Score
Weak1177.HK struggles to sustain strong margins.
Key Financial Metrics
Is 1177.HK Expensive or Cheap?
P/E Ratio
1177.HK trades at 36.85 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 1177.HK's PEG of 1.43 indicates fair valuation.
Price to Book
The market values Sino Biopharmaceutical Limited at 2.82 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 10.58 times EBITDA. This signals the market has high growth expectations.
How Well Does 1177.HK Make Money?
Net Profit Margin
For every $100 in sales, Sino Biopharmaceutical Limited keeps $7.36 as profit after all expenses.
Operating Margin
Core operations generate 21.84 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.32 in profit for every $100 of shareholder equity.
ROA
Sino Biopharmaceutical Limited generates $3.08 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Sino Biopharmaceutical Limited generates strong operating cash flow of $9.20B, reflecting robust business health.
Free Cash Flow
Sino Biopharmaceutical Limited generates strong free cash flow of $7.97B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.45 in free cash annually.
FCF Yield
1177.HK converts 9.42% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
36.85
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.43
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.82
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.68
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.52
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.37
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.14
vs 25 benchmark
How 1177.HK Stacks Against Its Sector Peers
| Metric | 1177.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 36.85 | 31.84 | Worse (Expensive) |
| ROE | 7.32% | 548.00% | Weak |
| Net Margin | 7.36% | 24571.00% | Weak |
| Debt/Equity | 0.52 | 0.53 | Neutral |
| Current Ratio | 1.37 | 5.65 | Neutral |
| ROA | 3.08% | -82.00% (disorted) | Weak |
1177.HK outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Sino Biopharmaceutical Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
40.19%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-11.94%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
81.70%
Industry Style: Defensive, Growth, Innovation
High Growth